Replies to post #185527 on Biotech Values

[DewDiligence]

GILD—Simtuzumab phase-2 in IPF stopped for futility:

http://finance.yahoo.com/news/gilead-terminates-phase-2-study-230000133.html

Phase-2 Simtuzumab trials in NASH and PSC are unaffected by this decision.

[DewDiligence]

GILD acquires NASH compound from (private) Nimbus Therapeutics for $400M up-front:

http://finance.yahoo.com/news/gilead-sciences-announces-acquisition-nimbus-123000488.html

Gilead Sciences, Inc. and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under which Gilead will acquire Nimbus Apollo, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program. Nimbus Therapeutics will receive an upfront payment of $400 million, with the potential to receive an additional $800 million in development-related milestones over time.

The Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. NDI-010976 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2016 and Phase 1 data for the compound will be presented next month during an oral session at The International Liver Congress 2016 [EASL]...

GILD now has four NASH programs—each with a different MoA (#msg-109653984).